Disease Detail

ID DOID:1749
Name squamous cell carcinoma
Definition A carcinoma that derives_from squamous epithelial cells.
Source DiseaseOntology.org
Alt Ids DOID:5512
Path disease disease of cellular proliferation cancer cell type cancer carcinoma squamous cell carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA mutant Carboxyamidotriazole Orotate squamous cell carcinoma sensitive detail...
EGFR over exp GA201 squamous cell carcinoma sensitive detail...
EGFR over exp TAK-285 squamous cell carcinoma sensitive detail...
EGFR over exp BGB-283 squamous cell carcinoma sensitive detail...
EGFR wild-type Avitinib maleate squamous cell carcinoma no benefit detail...
Unknown unknown Prexasertib squamous cell carcinoma not applicable detail...
Unknown unknown Cemiplimab squamous cell carcinoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Recruiting
NCT03357757 Phase II Avelumab + Valproic acid Avelumab With Valproic Acid in Virus-associated Cancer (LATENT) Recruiting
NCT03391973 Phase II Pembrolizumab Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) (CUP) Recruiting
NCT03396471 Phase II Pembrolizumab Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary Recruiting
NCT03669718 Phase II Cemiplimab + ISA101b Cemiplimab A Randomized Phase 2 Study of Cemiplimab +/- ISA101b in HPV16-Positive OPC Recruiting